18:14 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
16:39 , Jan 12, 2018 |  BC Week In Review  |  Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
21:41 , Jan 10, 2018 |  BC Extra  |  Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
18:46 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy...
19:15 , Sep 15, 2017 |  BC Week In Review  |  Company News

Evotec and Abivax partner to target infectious diseases

Evotec AG (Xetra:EVT) and Abivax S.A.S. (Euronext Paris:ABVX) partnered to discover and develop compounds to treat viral infectious including respiratory syncytial virus (RSV), influenza and dengue fever. Abivax will identify targets and use its...
16:54 , May 12, 2017 |  BioCentury  |  Product Development

Stepwise to a cure

Phase IIa data for ABX464 from Abivax S.A.S. are a step in the right direction toward a functional cure, but the company will need to show the therapy can achieve much greater reductions in HIV...
20:01 , May 5, 2017 |  BC Week In Review  |  Clinical News

ABX464 reduces HIV reservoirs in Ph IIa trial

Abivax S.A.S. (Euronext:ABVX) said ABX464 for 28 days reduced HIV reservoirs as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs) in the Phase IIa ABX464-004 trial to treat HIV infection. Specifically,...
22:36 , May 2, 2017 |  BC Extra  |  Clinical News

Abivax doubles on HIV reservoir readout

Abivax S.A.S. (Euronext:ABVX) rose €10.50 (114%) to €19.70 after it said results of a Phase IIa study showed ABX464 reduced HIV reservoirs in chronically infected HIV patients.The small molecule inhibits viral replication by preventing rev-mediated...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

ABX464: Phase IIa started

Abivax began the double-blind, placebo-controlled, European Phase IIa ABX464-004 trial to evaluate 50 mg oral ABX464 once daily for 28 days with Prezista darunavir plus ritonavir or with Prezista plus Tybost cobicistat in...